VectivBio Holding AG
NASDAQ: VECT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Luca Santarelli
- Headquarters
- Basel, Switzerland
- IPO year
- 2021
- Market cap
- $1.1B
- Website
- https://vectivbio.com
Loading VECT…
Loading profile data…Frequently asked questions about VECT
What does VectivBio Holding AG (VECT) do?
VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to identifying, developing, and commercializing treatments for severe rare medical conditions. The company's primary therapeutic focus is apraglutide, a prolonged-acting synthetic peptide analog of glucagon-like peptide-2. This compound is currently in a Phase III clinical...
Where does VECT trade?
VectivBio Holding AG (VECT) trades on the NASDAQ Global Select.
What sector is VECT in?
VectivBio Holding AG (VECT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of VectivBio Holding AG?
Luca Santarelli is the chief executive officer of VectivBio Holding AG (VECT).
Where is VectivBio Holding AG headquartered?
VectivBio Holding AG is headquartered in Switzerland.
Does VECT pay a dividend?
VectivBio Holding AG (VECT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VECT go public?
VectivBio Holding AG (VECT) completed its initial public offering in 2021.